BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19374036)

  • 1. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
    Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
    Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 3. Sunitinib-induced pseudoporphyria.
    Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
    Saylor PJ; Reid TR
    J Clin Oncol; 2007 Aug; 25(23):3544-6. PubMed ID: 17687160
    [No Abstract]   [Full Text] [Related]  

  • 5. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
    de Lima Lopes G; Rocha Lima CM
    Pharmacotherapy; 2007 May; 27(5):775-7. PubMed ID: 17461715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib and Thrombosis.
    Lamba G; Deol R; Shah D; Sahni R; Malhotra BK
    J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S128-30. PubMed ID: 21881834
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):261-6. PubMed ID: 17945482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome after treatment with sunitinib malate?
    Mulherin B; Loconte NK; Holen KD
    Oncology (Williston Park); 2008 Jan; 22(1):66-7, 70-1. PubMed ID: 18251284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute severe hypothyroidism induced by sunitinib.
    Prat A; Serrano C; Valverde C; Calvo E
    Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
    [No Abstract]   [Full Text] [Related]  

  • 12. Sunitinib.
    Heng DY; Kollmannsberger C
    Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.
    Kefeli U; Buyuberber S; Akyol M; Yildiz R; Kaplan MA; Ciltas A; Sevinc A; Karaca H; Seker M; Ozdemir N; Alacacioglu A; Coskun U; Isikdogan A; Dane F; Gumus M; Ozkan M; Suner A; Tarhan MO; Benekli M
    Hepatogastroenterology; 2013 Jun; 60(124):647-52. PubMed ID: 23165189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient sunitinib resistance in gastrointestinal stromal tumors.
    Bracci R; Maccaroni E; Cascinu S
    N Engl J Med; 2013 May; 368(21):2042-3. PubMed ID: 23697529
    [No Abstract]   [Full Text] [Related]  

  • 17. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
    Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
    ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
    Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor.
    Bar-Sela G; Kedem E; Hadad S; Pollack S; Haim N; Atrash F; Shahar E
    Jpn J Clin Oncol; 2010 Feb; 40(2):163-5. PubMed ID: 19797416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of sunitinib in an obese patient with a GIST.
    Desar IM; Burger DM; Van Hoesel QG; Beijnen JH; Van Herpen CM; Van der Graaf WT
    Ann Oncol; 2009 Mar; 20(3):599-600. PubMed ID: 19153120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.